X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
Company continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications Enrollment update on Phase 3 WHIM trial expected in mid-2021 Initial data from ongoing Phase 1b trial in Waldenström's macroglobulinemia to be presented at EHA Meeting in June 2021 Conference call today at 8:30 a.m. ET BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the first quarter ended March 31, 2021. The
